How Did Conferences Evolve Around the World this Year within the Pharma and Biopharma Industries?

As a service organization, KCAS works to be as collaborative as possible to help our clients during the drug development process. For us, the personal touch is integral to building solid business relationships. Having to rely on email and on-line meetings can’t really compensate for …

How Did Conferences Evolve Around the World this Year within the Pharma and Biopharma Industries? Read More »

BioAnalysis Zone’s Interview with KCAS’s Jeff Hester, Ph.D. on Cell & Gene Therapy

Recently, KCAS's Senior Director of BioPharma Services, Jeff Hester, PhD, was invited by Bioanalysis Zone to discuss key developments in the emerging field of Cell & Gene Therapy products (CGT). Along with other industry opinion leaders Stephanie Pasas Farmer, PhD (Ariadne Software, KS, USA) and …

BioAnalysis Zone’s Interview with KCAS’s Jeff Hester, Ph.D. on Cell & Gene Therapy Read More »

Staying Abreast of Changes and Interpretations of FDA Guidances and Regulatory Observations

Immunogenicity risk assessment has grown as a significant part of Protein therapeutics for Pre-Clinical and Clinical testing for regulatory submissions. Based on this, it is the requirement of CROs, who provide clients with Immunogenicity assays and data, to keep abreast of any changes or interpretations …

Staying Abreast of Changes and Interpretations of FDA Guidances and Regulatory Observations Read More »

Scroll to Top